Britannia Life Sciences Inc. Enters into $11.3 Million Share Exchange Agreement with McEwen Inc. and Britannia Mining Solutions Inc.
Toronto, Ontario--(Newsfile Corp. - November 3, 2025) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") is pleased to announce that it has entered into a share exchange agreement (the "Agreement") with McEwen Inc. ("McEwen") and Britannia Mining Solutions Inc. (doing business as Paragon Geochemical Laboratories Inc.) (together, "Paragon").Pursuant to the terms of the Agreement, McEwen will acquire 648,002 common shares of Paragon from Britannia at a deemed price of $17.50 per Paragon share, payable in common shares...
2025-11-03 7:07 AM EST
Britannia Life Sciences Inc. Delays Closing of Debenture Offering
Toronto, Ontario--(Newsfile Corp. - September 19, 2025) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") announced today that the closing of its previously announced non-brokered private placement offering of unsecured debentures (the "Debentures") for gross proceeds of up to CAD$10 million (the "Offering") will be delayed until September 30, 2025 or such other date as the Company and subscribers may agree. The Offering was initially expected to close on or before September 15, 2025.The Debentures are...
2025-09-19 5:00 PM EDT
Britannia Life Sciences Inc. Announces $10 Million Debenture Offering to Provide Investor Access to Asset-Backed Loan Portfolio
Toronto, Ontario--(Newsfile Corp. - July 28, 2025) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") is pleased to announce the launch of a non-brokered private placement offering of unsecured debentures (the "Debentures") for gross proceeds of up to $10 million CAD.The proceeds from the offering will be used to provide debenture holders of Britannia with exposure to a fixed return generated by a portfolio of asset-backed loans, offering strong underlying collateral backing and monthly interest income, beginning...
2025-07-28 8:46 AM EDT
Britannia Life Sciences Provides a Corporate Update
$5mm treasury investment in asset backed loansLooking to leverage royalty and private debt opportunitiesParagon Advanced Labs progresses towards listingToronto, Ontario--(Newsfile Corp. - July 8, 2025) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") is pleased to announce that it has committed $5 million of its treasury capital, generated from the sale of its former UK operating subsidiary, into an arm's length portfolio of asset-backed loans (the "Investment"). The loan portfolio is comprised of secured, asset-backed loans...
2025-07-08 8:30 AM EDT
Britannia Life Sciences Inc. Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - January 28, 2025) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") is pleased to provide the following corporate update to its shareholders:Sale of UK Operating SubsidiaryAs announced recently, Britannia successfully completed the sale of Advanced Development and Safety Laboratories Inc. ("ADSL"), its UK operating subsidiary (the "Transaction"). Net proceeds from the Transaction, after settling debt, intercompany loans, and minority interests, are approximately $13 million at the time of closing, with additional earnout payments...
2025-01-28 4:10 PM EST
Britannia Life Sciences Announces Strategic Divestiture of UK Operating Subsidiary
Britannia selling its UK lab and testing business to a private UK-based acquiror for total enterprise value of up to £24.2 million (CAD$43.6 million)Initial consideration of £18.7 million (CAD$33.7 million) payable in cash on closingAdditional consideration of up to £5.5 million (CAD$9.9 million) payable contingent on achieving certain EBITDA targets at March 2025 and December 2025.After the disposition Britannia will be debt free with assets that consist of significant cash reserves, and shares in Britannia Mining Solutions and Cosmetics LabToronto,...
2025-01-09 8:30 AM EST
Britannia Life Sciences Inc. Announces Results of Annual Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - November 14, 2024) - Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) ("Britannia" or the "Company") is pleased to announce the results of its annual general and special meeting of shareholders held on November 12, 2024, in Toronto (the "Meeting").All matters presented for approval at the Meeting were duly authorized and approved, as follows:Electing each of Scott Secord, Peter Shippen and Greg Taylor as directors of the Company to hold office for the ensuing year;Re-appointing Zeifmans...
2024-11-14 4:30 PM EST
Britannia Launches Financing to Support Britannia Mining Solutions Lab Rollout
Toronto, Ontario--(Newsfile Corp. - October 10, 2024) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") today announced a financing initiative (the "Financing") to fund the continued growth and expansion of its partially owned subsidiary, Britannia Mining Solutions Inc. ("BMS"). BMS specializes in providing innovative and efficient assay and geochemical services to the mining sector, with a particular focus on utilizing cutting-edge technologies such as PhotonAssay™ to deliver more accurate results and faster turnaround times for clients.The Financing...
2024-10-10 8:00 PM EDT
Britannia Life Sciences Inc. Announces Revocation of Failure-to-File Cease Trade Order
Toronto, Ontario and London, United Kingdom--(Newsfile Corp. - September 6, 2024) - Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) ("Britannia" or the "Company") is pleased to announce that on September 4, 2024, the Ontario Securities Commission (the "OSC"), the Company's principal regulator, issued an order revoking the failure-to-file cease trade order that it imposed against the Company on August 2, 2024 (the "CTO"). The CTO was imposed following the Company's failure to file its audited annual financial statements and...
2024-09-06 3:28 PM EDT
Britannia Life Sciences Inc. Reports Fourth Quarter and Fiscal Year Financial Results for 2024
Toronto, Ontario--(Newsfile Corp. - September 2, 2024) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") is pleased report its financial results for the year ended March 31, 2024. The Company's audited annual financial statements and related management's discussion and analysis for the year ended March 31, 2024, are available for review on SEDAR+ (www.sedarplus.ca) under the Company's issuer profile.Financial highlights for the financial year ended March 31, 2024, include (all amounts are presented in Canadian dollars unless...
2024-09-02 11:03 AM EDT
Britannia Life Sciences Inc. Provides Update on Cease Trade Order
Toronto, Ontario and London, United Kingdom--(Newsfile Corp. - August 26, 2024) - Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) ("Britannia" or the "Company") is providing an update on the status of the cease trade order (the "CTO") imposed on August 2, 2024, by the Ontario Securities Commission (the "OSC"), under National Policy 11-207 ("NP 11-207"), following the Company's failure to file its audited annual financial statements and related annual management's discussion and analysis ("MD&A") for the financial year ended...
2024-08-26 9:06 AM EDT
Britannia Life Sciences Inc. Provides Update on Cease Trade Order
Toronto, Ontario and London, United Kingdom--(Newsfile Corp. - August 12, 2024) - Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) ("Britannia" or the "Company") is providing an update on the status of the cease trade order (the "CTO") imposed on August 2, 2024, by the Ontario Securities Commission (the "OSC"), under National Policy 11-207 ("NP 11-207"), following the Company's failure to file its audited annual financial statements and related annual management's discussion and analysis ("MD&A") for the financial year ended...
2024-08-12 9:00 AM EDT
Gold Rush 2.0: Britannia Mining and Paragon Geochemical Bring Cutting-Edge Assaying Technology to the West Coast
Recently commissioned PhotonAssay™ unit at Paragon's newly built Surrey, BC, facility Represents Paragon's second PhotonAssay™ unit globally, following the commissioning of its PhotonAssay™ unit in Hamilton, Ontario, earlier this year Paragon expects to roll out an additional 10 PhotonAssay™ units before the end of 2025, bringing its total number of PhotonAssay™ units globally to 12 Toronto, Ontario and Surrey, British Columbia--(Newsfile Corp. - August 6, 2024) - Britannia Life Sciences Inc. (CSX: BLAB) (FSE: L020) and its wholly-owned subsidiaries, Britannia...
2024-08-06 9:47 AM EDT
Britannia Life Sciences Inc. Provides Update on Audit of Year-End Financial Statements and Expected Failure to File Cease Trade Order
Toronto, Ontario and London, United Kingdom--(Newsfile Corp. - July 29, 2024) - Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) ("Britannia" or the "Company") announces today an update regarding its ongoing audit process and delay in completing its Annual Filings (defined below) for the financial year ended March 31, 2024. Despite diligent efforts, the Company will be unable to complete, by the deadline of July 29, 2024 (the "Filing Deadline"), its Annual Filings for the financial year ended March 31,...
2024-07-29 4:30 PM EDT
Britannia Announces Closing of Offering of Unsecured Debenture Units
Britannia completes previously announced non-brokered private placement for aggregate gross proceeds of CAD$931,000Toronto, Ontario and London, United Kingdom--(Newsfile Corp. - July 22, 2024) - Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) ("Britannia" or the "Company") is pleased to announce the closing of its previously announced non-brokered private placement of unsecured debenture units (the"Units") for gross proceeds of $932,000.As announced on June 7, 2024, each Unit consists of (i) a CAD$1,000 principal amount unsecured, subordinated debenture (the "Debenture"), and (ii)...
2024-07-22 4:00 PM EDT
Britannia Announces Non-Brokered Private Placement of Unsecured Debenture Units
Britannia will undertake a non-brokered private placement of units consisting of subordinated dentures and common shares for aggregate gross proceeds of up to CAD$1,000,000Toronto, Ontario and London, United Kingdom--(Newsfile Corp. - June 7, 2024) - Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) ("Britannia" or the "Company"), today announced that it is undertaking a private placement of unsecured debenture units.This non-brokered private placement of subordinated debenture units (the "Units") at a price CAD$1,000 per Unit for aggregate gross proceeds of...
2024-06-07 4:47 PM EDT
Britannia Establishes U.S. Consumer Products Division
New cosmetic product safety regulations in the U.S. will usher in more stringent compliance and reporting requirements ADSL to initially offer U.S. clients access to its technology-enabled safety and registration platform, as well as Responsible Person services U.S. service offering to be enhanced with the addition of formulations, consumer trials, and artificial transdermal testing in early 2024Toronto, Ontario and London, United Kingdom--(Newsfile Corp. - December 18, 2023) - Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) ("Britannia") is pleased to...
2023-12-18 8:30 AM EST
Britannia Life Sciences Appoints Mark Bowes-Cavanagh to Lead Growth of Global Consumer Products Division
Mark-Bowes-Cavanagh has been appointed Chief Executive Officer of Britannia's growing global consumer compliance and regulatory businessMr. Bowes-Cavanagh will continue in his role as Chief Technical Officer of Britannia and Managing Director of Britannia's subsidiary, Advanced Development and Safety LaboratoriesMr. Bowes-Cavanagh is a seasoned executive with over 25 years of commercial and technical experience in the consumer products testing, inspection, and compliance sectorToronto, Ontario and London, United Kingdom--(Newsfile Corp. - December 12, 2023) - Britannia Life Sciences Inc. (CSE: BLAB) (FSE:...
2023-12-12 8:30 AM EST
Britannia Life Sciences Joins Forces with the ACI and ChemID to Facilitate UK CBD Market Access
Through its subsidiary, ADSL, Britannia will provide a variety of analytical and regulatory compliance services to the ACI's Green Bridge Gateway. Strategic partnership provides UK CBD market access through a "one-stop-shop" with assured compliance, product development and traceability.Britannia welcomes Kasia Tate, Regulatory Compliance Director of ADSL, who will oversee and manage the partnership.Toronto, Ontario and London, United Kingdom--(Newsfile Corp. - December 11, 2023) - Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) ("Britannia") is pleased to announce the launch of...
2023-12-11 8:50 AM EST
Britannia Life Sciences Inc. Announces Second Quarter Results
Toronto, Ontario--(Newsfile Corp. - November 29, 2023) - Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) ("Britannia" or the "Company") is pleased to provide its unaudited financial results for the three- and six- month periods ended September 30, 2023. These filings and additional information regarding Britannia are available for review on SEDAR at www.sedar.com. All amounts are Canadian dollars unless otherwise stated."We are pleased that the first six months of Fiscal 2023 saw revenue growth of 29% versus the...
2023-11-29 9:17 AM EST